TIDMCRX

RNS Number : 7514R

Cyprotex PLC

13 December 2016

Cyprotex PLC

("Cyprotex" or "the Company")

Director Dealing

Cyprotex PLC (AIM: CRX), a specialist Contract Research Organisation, announces that it was notified on 12 December 2016 that, on 8 December 2016, John Dootson, Chief Financial Officer, transferred 36,000 ordinary shares of 1p each in the Company ("Ordinary Shares") from an account in his own name to his wife Sandra Dootson for nil consideration by way of a gift. Following this transfer, John Dootson's' beneficial interest in the Company's Ordinary Shares remains unchanged at 68,928 Ordinary Shares, representing 0.31% of the Company's total issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  ------------------------------------------------------- 
 a)   Name                       John Kevin Dootson 
---  -------------------------  ---------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------- 
 a)   Position/status            Director of Cyprotex PLC 
---  -------------------------  ---------------------------- 
 b)   Initial notification       Initial Notification 
       /Amendment 
---  -------------------------  ---------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  ------------------------------------------------------- 
 a)   Name                       Cyprotex PLC 
---  -------------------------  ---------------------------- 
 b)   LEI                        N/A 
---  -------------------------  ---------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ------------------------------------------------------- 
 a)   Description of             Ordinary Shares of 1p each 
       the financial 
       instrument, type 
       of instrument 
                                  ISIN Code: GB00BP25RZ14 
       Identification 
       code 
---  -------------------------  ---------------------------- 
 b)   Nature of the              Transfer of Ordinary Shares 
       transaction 
---  -------------------------  ---------------------------- 
 c)   Price(s) and volume(s)       Price(s):    Volume(s): 
                                    nil          36,000 
---  -------------------------  ---------------------------- 
 d)   Aggregated information     N/A 
 
 
       - Aggregated volume 
 
 
       - Price 
---  -------------------------  ---------------------------- 
 e)   Date of the transaction    08/12/2016 
---  -------------------------  ---------------------------- 
 f)   Place of the transaction   London Stock Exchange 
---  -------------------------  ----------------------------

For further information:

 
 Cyprotex PLC                         Tel: +44 (0) 1625 
                                       505 100 
 Dr Anthony Baxter, Chief Executive   ir@cyprotex.com 
  Officer                              www.cyprotex.com 
  John Dootson, Chief Financial 
  Officer 
  Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 
 N+1 Singer (Nomad & Broker)          Tel: +44 (0)20 7496 
                                       3000 
 Shaun Dobson                         shaun.dobson@n1singer.com 
  Jen Boorer                           jennifer.boorer@n1singer.com 
                                       www.n1singer.com

Notes to Editors

About Cyprotex PLC

Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe(R) PK, chemPK(TM) and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHGGGRPPUPQGAW

(END) Dow Jones Newswires

December 13, 2016 10:32 ET (15:32 GMT)

Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cyprotex Charts.
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cyprotex Charts.